Extracted data showed that CaMK2A, 2B and 2G were expressed at “lower” and 2D at comparable levels in gliomas (sub-classified into GBM, oligodendroglioma and astrocytoma) in comparison to the normal subjects (Supplementary Figure S1). This evidence concerns the gene CAMK2A and central nervous system cancer.